Portfolio Review: July 31, 2017


Earnings season roll call

Consumer discretionary

D.R. Horton ($36; DHI) grew earnings per share 15% to $0.76 in the June quarter, squeezing past the consensus by a penny. The homebuilder's revenue advanced 17% to 3.78 billion, also narrowly ahead of expectations. The volume of net sales orders rose 11%, down from 14% growth in the March quarter and 15% growth in the December quarter.

D.R. Horton raised its guidance for fiscal 2017 ending September, implying revenue of $4.0 billion to $4.2 billion in the current quarter (7% to 12% growth), versus the consensus of $4.12 billion at the time of the announcement. The stock slipped on the news but entered the report with a lot of momentum. The stock is up 33% in 2017 and near its highest level in more than a decade. D.R. Horton is a Buy and a Long-Term Buy.


Citizens Financial Group's ($35; CFG) per-share profits surged 37% to $0.63 in the June quarter, topping the consensus estimate by $0.04. Revenue, up 9% to $1.40 billion, also topped the consensus. Average deposits rose 7%, while average loan growth stood at 6%. Net interest margin also widened.

Management updated its 2017 guidance, now projecting net interest income at the high end of its 8% to 9% growth range and loan-loss provisions lower than previously expected. The bank also backed its prior loan-growth target of 5.5% to 7% for the year. Citizens plans to pay its previously announced dividend hike, a 29% increase to a quarterly rate of $0.18 per share, on Aug. 16; it still expects to increase its dividend to $0.22 per share in early 2018. Citizens Financial is a Focus List Buy and a Long-Term Buy.

Zions Bancorp ($46; ZION) said earnings per share surged 66% to $0.73 in the June quarter, surpassing the consensus by $0.11. Results benefited from 8% growth for net interest income, higher net interest margin, and lower credit losses. Zions' loans increased 3%, its deposit base 4%. The bank will pay its quarterly dividend of $0.12 per share on Aug. 24. Zions raised its distribution 50% last month. Zions is a Buy and a Long-Term Buy.

Health care

For the June quarter, Amgen's ($176; AMGN) per-share profits climbed 15% to $3.27, comfortably ahead of the consensus of $3.11. Sales crept up 2% to $5.81 billion, as Amgen's roster of new products offset declines from its top-selling drugs. Revenue slipped 1% for Enbrel, a rheumatoid-arthritis treatment, and 5% for chemo drug Neulasta; these drugs combined for 46% of the company's total revenue.

The shares fell on the report, likely due to disappointment over management's guidance. Amgen raised its 2017 guidance for per-share profits, though the new range's midpoint of $12.40, implying 6% growth, remains below the consensus of $12.48. Management narrowed its target for 2017 revenue to a range with a midpoint of $22.75 billion, down 1% but above the consensus of $22.69 billion. Amgen is a Buy and a Long-Term Buy.

Laboratory Corp. of America ($161; LH) said June-quarter earnings per share increased 5% to $2.47 excluding special items, topping the consensus by $0.07. Net revenue advanced 5% to $2.50 billion. The diagnostics unit grew sales 8%, overcoming a 3% decline for the smaller drug-development business. LabCorp raised its 2017 outlook for profits and sales, both exceeding consensus estimates at the time of the announcement. Shares rallied on the results. LabCorp is a Long-Term Buy.


Alaska Air Group ($88; ALK) earned $2.51 per share excluding special items in the June quarter, up 18% but a penny short of the consensus. Revenue climbed 41% to $2.10 billion, matching analysts' forecasts. Passenger revenue per available seat mile, or unit revenue, increased 1.3%. Although Alaska Air grew its customer base, management described "a number of operational challenges," likely stemming from its December acquisition of Virgin America. Operating expenses surged 50%, largely due to the Virgin deal, rising wages, and 12% higher fuel cost per gallon. Alaska Air remains a Buy and a Long-Term Buy.

For the June quarter, Ingersoll-Rand ($87; IR) said earnings per share from continuing operations rose 8% to $1.49, surpassing the consensus estimate of $1.46. Sales, up 6% to $3.91 billion, also topped expectations. Bookings growth slowed to 3% from 6% in the March quarter. The company now expects 2017 earnings per share of $4.50, the high end of its prior range of $4.35 to $4.50 but still below the consensus of $4.53 at the time of the announcement. Management also sees full-year operating cash flow and free cash flow at the top of its previously announced ranges. Shares fell on the report but remain up 16% for the year. Ingersoll is a Long-Term Buy.


Facebook's ($166; FB) per-share profits surged 69% to $1.32, well ahead of the consensus estimate of $1.13. Sales, up 45% to $9.32 billion, also topped the consensus. Mobile advertising accounted for 87% of ad revenue, up from 84% in the year-ago quarter. Operating expenses rose by one-third as Facebook's work force swelled 43%. Daily average users grew 17% to $1.32 billion. Operating cash flow jumped 46% to $5.36 billion, marking the 12th straight quarter of growth exceeding 25%. Facebook is a Buy and a Long-Term Buy.

Juniper Networks ($28; JNPR) grew June-quarter earnings per share 14% to $0.57 excluding special items, topping the consensus by $0.03. Sales, up 9% to $1.31 billion, also narrowly surpassed the consensus. Revenue from services (up 9%) and switching (up 32%) more than offset softness in routing (flat) and security (down 12%). Management's September-quarter guidance was roughly in line with consensus estimates, which calls for flat profits on 3% revenue growth. Juniper is a Buy and a Long-Term Buy.

Lam Research ($168; LRCX) earned $3.11 per share excluding special items in the June quarter, up 73% and $0.08 above the consensus, on 51% sales growth. The company projects growth of 50% in sales and 80% in profits for the September quarter, both well above the consensus. Lam is a Focus List Buy and a Long-Term Buy.

Corporate roundup

Applied Materials ($47; AMAT) named Dan Durn as its new CFO, replacing the retiring Bob Halliday. Durn was most recently the CFO at NXP Semiconductors ($110; NXPI). Applied Materials is a Buy and a Long-Term Buy.

J.P. Morgan Chase ($92; JPM) agreed to pay $77 million to settle an investor lawsuit accusing the bank of manipulating benchmark interest rates. Separately, J.P. Morgan formed an online partnership with PayPal ($59; PYPL) that lets Chase customers add their credit cards to PayPal accounts through the digital wallet Chase Pay. J.P. Morgan is a Buy and a Long-Term Buy.

Celgene ($138; CELG) agreed to pay $280 million to settle a U.S. lawsuit claiming the company marketed cancer drugs for unapproved uses. Celgene is a Focus List Buy and a Long-Term Buy.

EQT Midstream Partners ($76; EQM) announced a cash distribution of $0.935 per unit, payable Aug. 14, up 5% from last quarter. EQT Midstream, a master limited partnership (MLP), has now raised its distribution in 17 straight quarters. EQT is a Long-Term Buy.

Rank Changes

No changes were made this week in Dow Theory Forecasts.

Current Hotline

Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at individualstockreports.com